Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 for levodopa-induced dyskinesia in Parkinson's disease
2008-006270-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AFQ056 with Placebo (2 arms). Primary endpoint: Abnormal Involuntary Movement Scale. Started Dec 2008; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2008-006270-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006270-15.